Lead (Pb) exposure hinders brain development in children by mechanisms that remain unknown. Previous evidence shows that sequestration of Pb in the choroid plexus lowers the production and secretion of transthyretin (TTR), a thyroxine (T 4 ) transport protein, from the choroid plexus into the cerebrospinal fluid (CSF). This study was undertaken to characterize the uptake kinetics of T 4 by the choroid plexus and to determine if in vivo Pb exposure altered the T 4 uptake in an in situ perfused ovine choroid plexus model. Sheep received ip injections of Pb acetate (20 mg Pb/kg) or Na acetate (as the controls) every 48 h for a period of 16 d. The [ 125 I]T 4 uptake was determined by a paired-tracer perfusion method using 0.5μCi [ 125 I]T 4 and 2 μ Ci [ 14 C]mannitol at various concentrations of unlabeled T 4 (trace to 20 μM). The flux of [ 125 I]T 4 into the choroid plexus followed Michaelis-Menten kinetics with the maximum flux (V max ) of 56.6 nmol/min/g and halfsaturation constant (K m ) of 10.7 μmol/L, suggesting an evident saturable influx of T 4 into the choroid epithelium. In vivo Pb exposure in these sheep resulted in a significant accumulation of Pb in the choroid plexus and hippocampus. Pb treatment diminished the V max by 63.7% of control, but did not alter K m . The maximal cellular uptake (U max ) and net uptake (U net ) in Pb-treated animals were 2.1-fold and 1.9-fold, respectively, lower than those of control. Exposure to Pb, however, did not significantly change the flow rate through the choroid plexus. Data suggest that the choroid plexus may serve as a significant site for T 4 transport into the CSF, and Pb exposure may hinder the influx of T 4 from the blood into the choroid plexus. The brain requires, but does not synthesize, thyroid hormones for its normal development, maturation, metabolism, and function (Dussault & Ruel, 1987;Legrand, 1984). Although thyroxine (T 4 ), a major type of thyroid hormone in blood and cerebrospinal fluid (CSF) circulation, is fairly lipophilic, the data from human and animal studies indicate that the transport of thyroxine between blood and the cerebrospinal fluid is restricted and does not follow simple diffusion mechanism responsive to mass balance (Ingenbleek & Young, 1994 Kirkegaard & Faber, 1991;Schreiber et al., 1990;Zheng et al., 2001). Thus, it has been suggested that the blood-brain barrier and/or blood-CSF barrier controls thyroxine availability to the cerebral compartment (Kirkegaard & Faber, 1991;van Raaij et al., 1994).Thyroxine enters the CSF and brain parenchyma by two possible routes. The hormone may cross the blood-brain barrier located at the cerebral capillary endothelium into the brain extracellular fluid (ECF) and then by diffusion enter the CSF. This proposed mechanism is supported by the observation of a wide distribution of radiolabeled [ 125 I]T 4 throughout the brain after intravenous injection, but not with intracerebroventricular (icv) injection of free [ 125 I]T 4 (Blay et al., 1993), although the possibility of interference fro...